secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001140361-23-058974
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Ionis/AstraZeneca WAINUA (eplontersen) for hATTR polyneuropathy
----------------------------------------------------------------------------

- Approval based on Phase 3 NEURO-TTRansform 35-week interim; co-primary endpoints of serum TTR and mNIS+7 and Norfolk QoL-DN showed sustained benefit.
- WAINUA is the only self-administered auto-injector treatment for ATTRv-PN; available in U.S. in January 2024.
- Global regulatory reviews underway; AstraZeneca holds commercialization rights outside U.S., recently expanded to Latin America.
- Eplontersen also in Phase 3 CARDIO-TTRansform for ATTR-CM, fully enrolled with >1,400 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123058974/0001140361-23-058974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123058974/ef20017247_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-058974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer